PET/CT imaging for prostate cancer patients becomes more accurate and available
RSU Nuclear medicine clinic offers more accurate and available PSMA PET/CT scan for prostate cancer patients using new radiopharmaceutical ¹⁸F-PSMA.
The new radiopharmaceutical ¹⁸F-PSMA is alternative to ⁶⁸Ga-PSMA-11 and has been developed and implemented in cooperation with the Center of Nuclear Medicine, Radiology Research Laboratory Riga Stradins University, and leading foreign radiology research centers and clinics. The new radiopharmaceutical is more sensitive at lower PSA levels, which guaranties even more accurate detection of prostate cancer.
"We have invested a lot of effort and resources to make PET/CT imaging more affordable for prostate cancer patients. Although PE /CT with PSMA is the most accurate imaging method for detection and visualization of metastatic prostate cancer in newly diagnosed patients and those with recurrence, yet not everyone who needs it can afford it. We managed to lower the price for PET/CT diagnostics for prostate cancer patients, while improving diagnostic accuracy by introducing a new radiopharmaceutical. PET/CT imaging with ¹⁸F-PSMA allows you to save considerable financial resources, time and reduce the risks by helping to assess and predict effectiveness of various possible treatments.”
“RSU Nuclear medicine clinic” board member
⁶⁸Ga-PSMA, ¹⁸F-PSMA, Prostate Cancer